Section of Gastroenterology
Assistant Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730
|MD||1997||Keio University, School of Medicine||
|Residency||1999||Keio University, School of Medicine||Internal Medicine
|Fellowship||2000||Sano Kousei Hospital, Tochigi, Japan||Internal Medicine
|Fellowship||2001||Tachikawa Kyousai Hospital, Tokyo, Japan||Internal Medicine
|Fellowship||2004||Keio University Hospital, Tokyo, Japan||Gastroenterology
Dr. Sakuraba is a gastroenterologist with a special expertise in inflammatory bowel disease (IBD). His interests are focused on clinical and translational research in the field of IBD. Ongoing projects include advancing the effectiveness of combination therapy with an immunomodulator in anti-TNF treated IBD patients, elucidating the efficacy and safety of natalizumab in anti-TNF refractory Crohn's disease, optimization of novel biologic/immunomodulatory agents to treat refractory IBD, and analyzing the long term outcome of patients with microscopic colitis. His work is emphasized to improve understanding and clinical management of IBD.
Inflammatory bowel disease (Crohn’s disease, ulcerative colitis), microscopic (collagenous and lymphocytic) colitis, diagnostic and therapeutic endoscopy.
- Sakuraba A, Keyashian K, Correia C, Melek J, Cohen RD, Hanauer SB, Rubin DT: Natalizumab in crohn's disease: Results from a us tertiary inflammatory bowel disease center. Inflamm Bowel Dis 2013;19:621-626.
- Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Hirata I, Tanaka S, Ashida T, Matsui T: Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in crohn's disease. Inflamm Bowel Dis 2012;18:1480-1487
- Sakuraba A, Sato T, Kamada N, Kitazume M, Sugita A, Hibi T: Th1/th17 immune response is induced by mesenteric lymph node dendritic cells in crohn's disease. Gastroenterology 2009;137:1736-1745.
- Hibi T, Sakuraba A: Is there a role for apheresis in gastrointestinal disorders? Nat Clin Pract Gastroenterol Hepatol 2005;2:200-201.
- Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T: An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009;104:2990-2995.